Skip to main content
MedPathMedPath Home
Clinical Trials/RPCEC00000372
RPCEC00000372
Not yet recruiting
Phase 3

Study of the efficacy, safety and tolerability of Abexol (suspension) versus Abexol (tablets) in patients with gastrointestinal symptoms - ASATSG

ational Centre for Scientific Research0 sites100 target enrollmentMay 22, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsGastrointestinal symptomsSigns and Symptoms, DigestiveDigestive System Diseases

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Gastrointestinal symptoms
Sponsor
ational Centre for Scientific Research
Enrollment
100
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 22, 2021
End Date
April 1, 2022
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
ational Centre for Scientific Research

Eligibility Criteria

Inclusion Criteria

  • •Patients with non\-erosive erythomatous gastritis, both sexes, aged between 19 and 70 years, with gastrointestinal symptoms such as: epigastralgia (abdominal pain localized in the epigastric region), heartburn, nausea, heartburn, flatulence, regurgitation, belching, abdominal distension, feeling of rapid satiety, vomiting, anorexia incomplete, emptying sensation, attend an outpatient consultation at the Institute of Gastroenterology and agree to participate in the study by signing the informed consent.

Exclusion Criteria

  • •Patients with
  • •Confirmatory endoscopy of gastric, duodenal or esophageal ulcer.
  • •Organic lesions of the upper digestive tract that require specific treatment.
  • •Benign and malignant digestive neoplasms.
  • •Alarm symptoms (digestive bleeding, anemia, significant loss of body weight, progressive dysphagia, odynophagia, persistent vomiting, lymphadenopathy, palpation of abdominal mass).
  • •Active liver or kidney diseases.
  • •Other non\-digestive neoplasms.
  • •Thyroid gland disorders.
  • •Irritable bowel syndrome.
  • •Pancreatic conditions (acute or acute chronic pancreatitis).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Soft capsules with ozonated sunflower oil versus oral OLEOZON® in patients with GiardiosisGiardiosis
RPCEC00000440ational Centre for Scientific Research (CNIC)200
Active, not recruiting
Not Applicable
Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCE
EUCTR2005-006071-12-ITAZIENDA OSPEDALIERA SAN CAMILLO FORLANINI276
Recruiting
Not Applicable
Study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett's Esophagus - part 2
NL-OMON20279Aqua Medical, Inc.19
Completed
Phase 2
Study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett*s Esophagus - part 2Esophageal CarcinomaIntestinal Metaplasia1001799010017991
NL-OMON55125Academisch Medisch Centrum28
Completed
Phase 4
A clinical trial to study the effect of a Under eye Skin cream containing Biophytex LS 8740 and Proteasyl TP LS 8657 in patients with under eye dark circles.
CTRI/2010/091/001346Glenmark Pharmaceutical limited500